The perils of relying on anti-hepatitis B total core antibody in screening individuals infected with HIV

Int J STD AIDS. 2012 Feb;23(2):149-50. doi: 10.1258/ijsa.2011.011205.

Abstract

Co-infection with HIV and hepatitis B virus (HBV) has serious long-term consequences. We describe a case of an HIV-infected heterosexual black African man with a delayed diagnosis of HBV infection. Baseline HBV screening was performed using a sequential testing algorithm starting with a total core antibody (anti-HBc) test, which was negative. He had no evidence of immunity against HBV and subsequently received three unsuccessful courses of HBV vaccination. He had mild but persistent elevation of liver enzymes over a five-year period despite maintaining full suppression of HIV replication on efavirenz, lamivudine and zidovudine; the latter was changed to abacavir due to lipoatrophy. Further testing revealed e-antibody positive chronic HBV infection with undetectable anti-HBc reactivity. High-grade HBV viraemia associated with L180M and M240V drug-resistance mutations was confirmed. He was subsequently switched to a tenofovir-based regimen, which achieved HBV suppression. Adopting effective HBV screening strategies in HIV-infected patients is recommended.

Publication types

  • Case Reports

MeSH terms

  • Anti-HIV Agents / therapeutic use
  • Coinfection
  • HIV Infections / diagnosis*
  • HIV Infections / drug therapy
  • HIV Infections / virology
  • Hepatitis B Antibodies / blood*
  • Hepatitis B Core Antigens / immunology*
  • Hepatitis B Vaccines / administration & dosage
  • Hepatitis B Vaccines / immunology
  • Hepatitis B virus / immunology
  • Hepatitis B, Chronic / diagnosis*
  • Hepatitis B, Chronic / immunology
  • Hepatitis B, Chronic / virology
  • Humans
  • Male
  • Middle Aged
  • Viral Load

Substances

  • Anti-HIV Agents
  • Hepatitis B Antibodies
  • Hepatitis B Core Antigens
  • Hepatitis B Vaccines